Publicacións en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (5)

2023

  1. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

    The Lancet, Vol. 401, Núm. 10379, pp. 821-832

  2. Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

    Targeted Oncology, Vol. 18, Núm. 5, pp. 639-641

2016

  1. RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers

    European Journal of Cancer, Vol. 64, pp. 149-158

2012

  1. Systemic anticancer agents: Dermatologic indications and adverse events

    Comprehensive Dermatologic Drug Therapy: Expert Consult - Online and Print (Elsevier), pp. 397-407

  2. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis

    European Journal of Cancer, Vol. 48, Núm. 3, pp. 340-346